Chartwell Investment Partners LLC Sells 19,572 Shares of Tandem Diabetes Care Inc (TNDM)

Share on StockTwits

Chartwell Investment Partners LLC decreased its holdings in shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) by 26.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,346 shares of the medical device company’s stock after selling 19,572 shares during the quarter. Chartwell Investment Partners LLC owned about 0.09% of Tandem Diabetes Care worth $2,064,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. IFP Advisors Inc lifted its holdings in Tandem Diabetes Care by 78.4% in the 4th quarter. IFP Advisors Inc now owns 1,757 shares of the medical device company’s stock worth $66,000 after buying an additional 772 shares in the last quarter. US Bancorp DE lifted its holdings in Tandem Diabetes Care by 397.8% in the 3rd quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock worth $107,000 after buying an additional 1,989 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in Tandem Diabetes Care in the 3rd quarter worth $109,000. Meeder Asset Management Inc. lifted its holdings in Tandem Diabetes Care by 1,921.6% in the 3rd quarter. Meeder Asset Management Inc. now owns 2,709 shares of the medical device company’s stock worth $116,000 after buying an additional 2,575 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Tandem Diabetes Care in the 4th quarter worth $125,000. Institutional investors and hedge funds own 71.55% of the company’s stock.

A number of equities analysts have commented on the stock. Craig Hallum set a $59.00 price objective on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a report on Friday, November 2nd. BidaskClub upgraded shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 12th. Oppenheimer set a $57.00 price objective on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a report on Friday, November 2nd. Lake Street Capital set a $60.00 price objective on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a report on Saturday, November 3rd. Finally, UBS Group assumed coverage on shares of Tandem Diabetes Care in a report on Tuesday, November 27th. They issued a “neutral” rating and a $36.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Tandem Diabetes Care currently has an average rating of “Buy” and an average price target of $44.75.

In other news, EVP John F. Sheridan sold 20,000 shares of the business’s stock in a transaction dated Friday, January 25th. The shares were sold at an average price of $45.26, for a total value of $905,200.00. Following the completion of the sale, the executive vice president now owns 20,666 shares of the company’s stock, valued at approximately $935,343.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David B. Berger sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $40.08, for a total transaction of $400,800.00. Following the completion of the sale, the executive vice president now directly owns 11,765 shares of the company’s stock, valued at approximately $471,541.20. The disclosure for this sale can be found here. Insiders sold a total of 112,281 shares of company stock valued at $4,428,597 in the last three months. Insiders own 9.30% of the company’s stock.

TNDM opened at $42.29 on Friday. Tandem Diabetes Care Inc has a 1-year low of $2.14 and a 1-year high of $52.55.

TRADEMARK VIOLATION WARNING: “Chartwell Investment Partners LLC Sells 19,572 Shares of Tandem Diabetes Care Inc (TNDM)” was originally published by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://macondaily.com/2019/02/09/chartwell-investment-partners-llc-sells-19572-shares-of-tandem-diabetes-care-inc-tndm.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care Inc (NASDAQ:TNDM).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply